Applications of Antibodies and Immunoassays

Meulenberg, Eline P.

doi:10.1016/b978-0-12-409547-2.14416-6

Cited by 2 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies are extensively exploited in therapy, diagnosis, and basic science due to their high affinity and selectivity. 1 The field of antibody engineering appeared to reach its maturity with the discovery of directed evolution to optimize binding, with humanization to decrease immunogenicity, and, more recently, with the possibility to target cytotoxic molecules to cancer cells and to engineer bispecific molecules that engage immune cells. 2 However, in the past decade, several technologies that render antibodies activatable under particular stimuli have unravelled new avenues for antibodies as therapeutics and as probes to investigate biological systems.…”

Section: Activatable Antibodies For Every Stimulusmentioning

confidence: 99%

The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control

2021

View full text Add to dashboard Cite

The high selectivity and affinity of antibody binding have made antibodies all-pervasive tools in therapy, diagnosis, and basic science. A plethora of chemogenetic approaches has been devised to make antibodies responsive to stimuli ranging from light to enzymatic activity, temperature, pH, ions, and effector molecules. Within a single decade, the field of activatable antibodies has yielded marketed therapeutics capable of engaging antigens that could not be targeted with traditional antibodies, as well as new tools to control intracellular protein location and investigate biological processes. Many opportunities remain untapped, waiting for more efficient and generally applicable masking strategies to be developed at the interface between chemistry and biotechnology.

show abstract

Section: Activatable Antibodies For Every Stimulusmentioning

confidence: 99%

The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control

2021

View full text Add to dashboard Cite

show abstract

“…CEA is one of the first tumour-associated biomarkers to be identified and has consequently been well characterised [10]. CEA is a cell surface glycoprotein involved with cell adhesion [11], is associated with various types of cancers, and is vital in monitoring the effectiveness of remediation [8,12]. Further, this biomarker has a high molecular weight and is extensively used in the clinical diagnosis of colon, breast and ovarian tumours [13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%